Biotest Confirms 2025 Guidance Amid Revenue Decline

Biotest AG has confirmed its financial guidance for 2025 despite a substantial decline in first-quarter revenue. The company reported sales of €124.2 million, marking a 42.3% decrease from the previous year. This drop primarily stems from reduced revenue from technology disclosure and development services for Grifols, S.A., which fell by €65.6 million.

Product sales decreased by 18.4%, attributed to delayed releases of Intratect® batches. Despite this, human albumin and Yimmugo® sales rose by 17.0% and 10.2%, respectively. EBIT plummeted to €-23.0 million from €52.8 million the previous year, largely due to the decreased Grifols revenue.

Amid these challenges, Biotest affirmed its 2025 outlook, expecting a mid-single-digit sales decline. However, potential risks include instability in the Middle East and US tariffs on EU drugs. Operating results are projected between €-55.0 million and €-75.0 million, with ROCE ranging from -3% to -7%.